Matthew Winton - SEC Form 4 Insider Trading Activity

Summary

Updated Aug 4, 2026

Matthew Winton is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $117K.

Profile

Matthew Winton is the Chief Commercial and Business at CervoMed Inc. (CRVO). SEC records also connect Winton to Inozyme Pharma, Inc. (INZY). Winton has reported 6 insider filings with the SEC since 2024. The most recent filing was in February 2026.

RoleChief Commercial and Business
Notability34/100

Board memberships

Reported roles

Awards & honors

Track Record

InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.

Total purchases tracked3

Trading Pattern

InsiderAlpha's records for Matthew Winton go back to 2024: 6 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $39K (3 buys totaling $117K). The largest single buy on record is $76K of CRVO in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.

Career & Filing History

Every role Matthew Winton has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2025-11-19CRVOCervoMed Inc.P - Open-market purchase1.5K$7.95$12K
2025-11-19CRVOCervoMed Inc.P - Open-market purchase3.5K$8.43$30K
2025-11-17CRVOCervoMed Inc.P - Open-market purchase10.0K$7.57$76K
2025-07-01INZYInozyme Pharma, Inc.J - Other acquisition / disposition21.7K$4.00$87K
2024-10-03INZYInozyme Pharma, Inc.A - Grant or award1.7K$4.45$8K

Most Active Insiders Right Now

Matthew Winton has no recent co-filers at the same companies, so here are the insiders with the largest open-market activity across the market in the last 90 days.

More Notable Insiders

Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:

Frequently Asked Questions

Who is Matthew Winton?

Matthew Winton is the Chief Commercial and Business at CervoMed Inc. (CRVO). SEC records also connect Winton to Inozyme Pharma, Inc. (INZY). Winton has reported 6 insider filings with the SEC since 2024. The most recent filing was in February 2026.…

Has Matthew Winton been buying or selling stock?

Recorded transactions: 3 open-market purchases ($117K) and 0 open-market sales across all tracked filings.

How accurate is Matthew Winton's historical track record?

Across 3 tracked purchases, Matthew Winton averaged no 30-day data yet with a win rate pending. InsiderAlpha rates the track record at –/5 stars.

Where can I see all of Matthew Winton's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Matthew Winton profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.